Global Eye Cancer Market Research Report, By Type (Intraocular Cancer, Squamous Cell Cancer, Rhabdomyosarcoma), Treatment (Chemotherapy, Targeted Therapy, Surgery & Radiation Therapy, Hormone Therapy), End User (Hospital & Clinics) - Forecast till 2027
ID: MRFR/Pharma/3314-HCR | | Region: Global | 85 pages
Market Scenario:
Eye cancer occurs when healthy cells in or around the eye change and grow uncontrollably leading to the formation of tumors. Different types of eye cancers are observed namely intraocular cancer, squamous cell cancer, rhabdomyosarcoma, and others. These types of cancer affects eyeball, orbit (eye socket), and adnexal (accessory) structures. Over 100 types of cancers have been identified. According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered, which is expected to increase continuously in coming future. Additionally, as per the report published in American Society of Clinical Oncology, in 2015, over 3500 patients in the US were diagnosed with primary intraocular cancer. Because of deteriorating lifestyle due to alcoholism and smoking, there is a continued rise in the incidence of cancer. The global eye cancer market is majorly driven by the increasing prevalence of eye cancer across the globe. Additionally, increasing government support for research & development, rising healthcare expenditure and changing lifestyle has fuelled the market growth. Many types of treatment are available in the market, however, all the treatment show some or other side effects on the body. Side effects of the treatment, and high cost of the medicines may slow the growth of the market during the forecasted period.
The global eye cancer market is expected to grow at a CAGR of ~8.3 % during the forecast period 2017-2023.
Intended Audience
- Pharmaceutical Companies
- Government and private research companies
- Research and Development (R&D) Companies
- Drug Manufacturers and Suppliers
- Medical Research Laboratories
Figure 1- Market Synopsis of Global Eye Cancer Market Research, by Treatment 2016 (%)
Sources- WHO, cancer research UK, American Cancer Society
Segmentation
The global eye cancer market is segmented on the basis of types, treatment and end users.
On the basis of types, the market is segmented into intraocular cancer, squamous cell cancer, rhabdomyosarcoma, and others. Intraocular cancer is further segmented into melanoma of the eye, lymphoma of the eye, and eye cancers in children.
On the basis of treatment, the market is categorised into chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. Chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. Target therapy is sub segmented into monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers and others.
Regional Analysis
The Americas dominate the global eye cancer market owing to the increasing prevalence of people suffering with eye cancer. Additionally, well developed technology, high healthcare expenditure, and strong government support for research & development have fuelled the growth of the Americas eye cancer market. Furthermore, presence of the leading players in this region will support the growth in coming future.
Europe accounts for the second largest eye cancer market, which is followed by Asia Pacific. Strong government support and availability of the funds for research & development have driven the market growth. Asia Pacific is the fastest growing eye cancer market owing to the increasing prevalence of cancer, rapidly developing economy and increasing government support.
On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa eye cancer market. Kuwait, Qatar, Oman and South Arabia holds the major share in the Middle East market. However, Africa region is expecting a healthy growth due to presence of huge opportunity for the development of the market.
Market Assessment
Sources- WHO, cancer research UK, American Cancer Society
Key Players for Global Eye Cancer Market
Some of key the players in the market are Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Oncomed Pharmaceuticals (U.S.) and Immunomedics (U.S.).
Frequently Asked Questions (FAQ) :
Eye cancer market is expected to exhibit a CAGR of 8.3% from 2017 to 2023.
Eye cancer market is driven by the high prevalence of intraocular cancer.
High costs of medicines and adverse effects of the treatment can hamper the global eye cancer market growth.
The Americas can be highly lucrative for the global eye cancer market due to prevalence of patients with eye cancer.
Eli Lilly and Company, Janssen Biotech, Inc., Novartis AG, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc., Amgen, Inc., Spectrum Pharmaceuticals Inc., Oncomed Pharmaceuticals, Pfizer, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals, Immunomedics, AbbVie Inc., GlaxoSmithKline Plc., Bayer AG, and Sanofi are key players of the global eye cancer market.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Eye Cancer Market, by Types
6.1 Introduction
6.2 Intraocular Cancer
Market Estimates & Forecast, 2020 – 2027
6.3 Squamous Cell Cancer
Market Estimates & Forecast, 2020 – 2027
6.4 Rhabdomyosarcoma
Market Estimates & Forecast, 2020 – 2027
6.5 Others
Chapter 7. Global Eye Cancer Market, by Treatment
7.1 Introduction
7.2 ChemoTreatment
Market Estimates & Forecast, 2020 – 2027
7.2.1 Anthracyclines
7.2.2 Taxanes
7.2.3 Antimetabolites
7.2.4 Alkylating Agents
7.3 Surgery & Radiation Treatment
Market Estimates & Forecast, 2020 – 2027
7.4 Targeted Treatment
Market Estimates & Forecast, 2020 – 2027
7.4.1 Monoclonal Antibodies
7.4.2 Tyrosine Kinase Inhibitors
7.5 Hormone Treatment
Market Estimates & Forecast, 2020 – 2027
7.6 Biologic Treatment
Market Estimates & Forecast, 2020 – 2027
7.7 Other
Market Estimates & Forecast, 2020 – 2027
Chapter 8 Global Eye Cancer Market, by End User
8.1 Introduction
8.2 Hospital & Clinics
Market Estimates & Forecast, 2020 – 2027
8.3 Ambulatory Care Centers
Market Estimates & Forecast, 2020 – 2027
8.4 Others
Chapter 9. Global Eye Cancer Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Novartis AG
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 GlaxoSmithKline Plc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Bayer AG
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Amgen, Inc.
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Bristol-Myers Squibb Company
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Eli Lilly and Company
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 F. Hoffmann-La Roche Ltd.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical industry
Chapter 13 Appendix
LIST OF TABLES
Table 1 Eye Cancer Industry Synopsis, 2020 – 2027
Table 2 Global Eye Cancer Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Global Eye Cancer Market by Region, 2020 – 2027, (USD Million)
Table 4 Global Eye Cancer Market by Types, 2020 – 2027, (USD Million)
Table 5 Global Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 6 Global Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 7 North America Eye Cancer Market by Types, 2020 – 2027, (USD Million)
Table 8 North America Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 9 North America Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 10 US Market by Types, 2020 – 2027, (USD Million)
Table 11 US Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 12 US Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 13 Canada Market by Types, 2020 – 2027, (USD Million)
Table 14 Canada Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 15 Canada Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 16 South America Market by Types, 2020 – 2027, (USD Million)
Table 17 South America Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 18 South America Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 19 Europe Market by Types, 2020 – 2027, (USD Million)
Table 20 Europe Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 21 Europe Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 22 Western Europe Market by Types, 2020 – 2027, (USD Million)
Table 23 Western Europe Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 24 Western Europe Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 25 Eastern Europe Market by Types, 2020 – 2027, (USD Million)
Table 26 Eastern Europe Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 27 Eastern Europe Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 28 Asia Pacific Market by Types, 2020 – 2027, (USD Million)
Table 29 Asia Pacific Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 30 Asia Pacific Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 31 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)
Table 32 Middle East & Africa Eye Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 33 Middle East & Africa Eye Cancer Market by End Users, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Eye Cancer Market
Figure 3 Segmentation Market Dynamics for Global Eye Cancer Market
Figure 4 Global Eye Cancer market Share, by Type 2020
Figure 5 Global Eye Cancer market Share, by Treatment 2020
Figure 6 Global Eye Cancer Market Share, by End Users, 2020
Figure 7 Global Eye Cancer Market Share, by Region, 2020
Figure 8 North America Eye Cancer Market Share, by Country, 2020
Figure 9 Europe Eye Cancer Market Share, by Country, 2020
Figure 10 Asia Pacific Eye Cancer Market Share, by Country, 2020
Figure 11 Middle East & Africa Eye Cancer Market Share, by Country, 2020
Figure 12 Global Eye Cancer Market: Company Share Analysis, 2020 (%)
Figure 13 Novartis AG: Key Financials
Figure 14 Novartis AG: Segmental Revenue
Figure 15 Novartis AG: Geographical Revenue
Figure 16 GlaxoSmithKline Plc..: Key Financials
Figure 17 GlaxoSmithKline Plc..: Segmental Revenue
Figure 18 GlaxoSmithKline Plc..: Geographical Revenue
Figure 19 Bayer AG: Key Financials
Figure 20 Bayer AG: Segmental Revenue
Figure 21 Bayer AG: Geographical Revenue
Figure 22 Amgen, Inc.: Key Financials
Figure 23 Amgen, Inc.: Segmental Revenue
Figure 24 Amgen, Inc.: Geographical Revenue
Figure 25 Bristol-Myers Squibb Company: Key Financials
Figure 26 Bristol-Myers Squibb Company: Segmental Revenue
Figure 27 Bristol-Myers Squibb Company: Geographical Revenue
Figure 28 F. Hoffmann-La Roche Ltd.: Key Financials
Figure 29 F. Hoffmann-La Roche Ltd.: Segmental Revenue
Figure 30 F. Hoffmann-La Roche Ltd.: Geographical Revenue
Figure 31 AstraZeneca Plc: Key Financials
Figure 32 AstraZeneca Plc: Segmental Revenue
Figure 33 AstraZeneca Plc.: Geographical Revenue
